|
1.
|
|
18 p, 862.2 KB |
Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma
/
Chari, Ajai (Mount Sinai School of Medicine, USA) ;
Askari, Elham (Hospital Universitario Fundación Jiménez Díaz) ;
Caers, Jo (Centre Hospitalier Universitaire de Liège, Belgium) ;
Costa, Luciano J. (University of Alabama at Birmingham, USA) ;
Hilder, Brandi W. (Janssen Research & Development, Spring House, USA) ;
Krishnan, Amrita (City of Hope Comprehensive Cancer Center, Duarte, USA) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Minnema, Monique C. (University Utrecht, Netherlands) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pillarisetti, Kodandaram (Janssen Research & Development, Spring House, USA) ;
Van De Donk, Niels W.C.J. (Vrije Universiteit Amsterdam, Netherlands) ;
Rodríguez-Otero, Paula (Clínica Universidad de Navarra)
What is this summary about? This plain language summary describes the results of a phase 1 research study (or clinical trial) called MonumenTAL-1 published in the New England Journal of Medicine in December 2022. [...]
2023 -  10.2217/fon-2023-0332
Future oncology (London, England), Vol. 19 Núm. 27 (september 2023) , p. 1823-1840
|
|
|
2.
|
|
11 p, 396.3 KB |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics
/
Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ;
Schjesvold, Fredrik (University of Oslo) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Anderson, Larry D. (University of Texas Southwestern Medical Center) ;
White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Sonneveld, Pieter (Erasmus MC Cancer Institute) ;
Engelhardt, Monika (Universitätsklinikum Freiburg) ;
Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Corso, Alessandro (Hospital of Legnano) ;
Dürig, Jan (University Hospital Essen (Alemanya)) ;
Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ;
Salomo, Morten (Copenhagen University Hospital) ;
Beksac, Meral (Ankara University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ;
Liberati, Anna Marina (University of Perugia) ;
Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ;
Robak, Pawel (Medical University of Lodz) ;
Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ;
Yagci, Munci (Gazi University Medical Faculty) ;
Vural, Filiz (Ege University) ;
Kanate, Abraham (West Virginia University) ;
Jiang, Ruiyun (Bristol Myers Squibb) ;
Grote, Lara (Bristol Myers Squibb) ;
Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 - 10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83
|
|
|
3.
|
|
4 p, 756.5 KB |
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma : final analysis of PLEIADES and EQUULEUS
/
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu, France) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai, New York, USA) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid)) ;
Haenel, M. (Klinikum Chemnitz, Germany) ;
Touzeau, Cyrille (University Hospital Hôtel-Dieu, France) ;
Ailawadhi, Sikander (Mayo Clinic Florida, USA) ;
Besemer, Britta (Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Germany) ;
de la Rubia Comos, Javier (Catholic University of Valencia) ;
Encinas, Cristina (Hospital General Universitario Gregorio Marañón) ;
Mateos, M. V (Hospital Universitario de Salamanca) ;
Salwender, Hans (AK Altona and AK St. Georg, Hamburg, Germany) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Hulin, Cyrille (Hôpital Haut Lévêque. University Hospital, Pessac, France) ;
Karlin, Lionel (Centre Hospitalier Lyon Sud. Hospices Civils de Lyon, France) ;
Sureda Balari, Anna (Institut d'Investigació Biomèdica de Bellvitge) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Benboubker, Lotfi (Centre Hospitalier Régional Universitaire (CHRU), France) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ;
Tarantolo, Stefano (Nebraska Cancer Specialists, Omaha, USA) ;
Terebelo, Howard (Providence Cancer Center, Southfield, USA) ;
Yang, Shiyi (Janssen Research & Development. LLC, USA) ;
Wang, Jianping (Janssen Research & Development. LLC, USA) ;
Nnane, Ivo (Janssen Research & Development. LLC, USA) ;
Qi, Ming (Janssen Research & Development. LLC, USA) ;
Kosh, Michele (Janssen Research & Development. LLC, USA) ;
Delioukina, Maria (Janssen Research & Development. LLC, USA) ;
Goldschmidt, Hartmut (GMMG-Study Group at University Hospital Heidelberg, Germany)
2023 - 10.1038/s41408-023-00805-x
Blood Cancer Journal, Vol. 13 Núm. 1 (march 2023)
|
|
|
4.
|
|
14 p, 675.3 KB |
Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children
/
Galindo Zavala, Rocío (Hospital Regional Universitario de Málaga) ;
Bou, Rosa (Hospital Sant Joan de Deú) ;
Magallares López, Berta Paula (Institut d'Investigació Biomèdica Sant Pau) ;
Mir-Perelló, Concepción (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Palmou Fontana, Natalia (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Sevilla Pérez, Belén (Hospital Campus de la Salud) ;
Medrano-San Ildefonso, Marta (Hospital Universitario Miguel Servet (Saragossa)) ;
González-Fernández, M.I. (Hospital Universitari i Politècnic La Fe (València)) ;
Román-Pascual, Almudena (Hospital General de Villalba) ;
Alcañiz-Rodríguez, Paula (Hospital Virgen de la Arriaxaca) ;
Nieto-Gonzalez, Juan Carlos (Hospital General Universitario Gregorio Marañón) ;
López-Corbeto, Mireia (Hospital Universitari Vall d'Hebron) ;
Granã Gil, Jenaro (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
Osteoporosis incidence in children is increasing due to the increased survival rate of patients suffering from chronic diseases and the increased use of drugs that can damage bones. Recent changes made to the definition of childhood osteoporosis, along with the lack of guidelines or national consensuses regarding its diagnosis and treatment, have resulted in a wide variability in the approaches used to treat this disease. [...]
2020 - 10.1186/s12969-020-0411-9
Pediatric rheumatology online journal, Vol. 18 Núm. 1 (24 2020) , p. 20
|
|
|
5.
|
|
10 p, 1.1 MB |
Measuring the symbiotic performance of single entities within networks using an LCA approach
/
Arce Bastias, Fernando (Universidad Tecnológica Nacional. Consejo Nacional de Investigaciones Científicas y Técnicas) ;
Rodríguez, Paula Daniela (Universidad Tecnológica Nacional. Consejo Nacional de Investigaciones Científicas y Técnicas) ;
Arena, Alejandro Pablo (Universidad Tecnológica Nacional. Consejo Nacional de Investigaciones Científicas y Técnicas) ;
Talens Peiró, Laura (Universitat Autònoma de Barcelona. Institut de Ciència i Tecnologia Ambientals)
This paper introduces the Symbiotic Performance Indicator, a novel indicator aiming to quantify the environmental benefits generated by by-product exchanges in an industrial symbiosis network. Despite the significant advancements in assessing industrial symbiosis, the lack of indicators for individual entities involved in by-product exchanges hinders a comprehensive understanding of its environmental benefits. [...]
2023 - 10.1016/j.jece.2023.111023
Journal of environmental chemical engineering, Vol. 11, Issue 5 (October 2023) , art. 111023
|
|
|
6.
|
|
9 p, 1.1 MB |
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer
/
Pons, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Hernández-León, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Altaleb, Ahmad (Mubarak Al-Kabeer Hospital, Jabriya, Kuwait) ;
Ussene, Esperança (Hospital Vila Franca de Xira, Portugal) ;
Iglesias, Roman (Hospital Santa Barbara, Ciudad Real) ;
Castillo, Ana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodríguez-Martínez, Paula (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Castellà Fernández, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quiroga, Vanesa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Felip, Eudald (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Cirauqui, Beatriz (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Margelí, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernández, Pedro Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Digital counting methods were developed to decrease the high intra- and inter-observer variability of immunohistochemical markers such as Ki67, with most presenting a good correlation coefficient (CC). [...]
2022 - 10.1038/s41598-022-11411-5
Scientific reports, Vol. 12 (may 2022)
|
|
|
7.
|
|
19 p, 9.2 MB |
Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype
/
Renau-Mínguez, Chantal (University of Valencia-FISABIO Joint Unit) ;
Herrero Abadía, Paula (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Ruiz-Rodriguez, Paula (University of Valencia-FISABIO Joint Unit) ;
Sentandreu, Vicente (University of Valencia) ;
Torrents, Eduard (Universitat de Barcelona) ;
Chiner-Oms, Álvaro (Instituto de Biomedicina de Valencia (IBV-CSIC)) ;
Torres-Puente, Manuela (Instituto de Biomedicina de Valencia (IBV-CSIC)) ;
Comas, I (Instituto de Biomedicina de Valencia (IBV-CSIC)) ;
Julián Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Coscolla, Mireia (University of Valencia-FISABIO Joint Unit)
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. [...]
2023 - 10.3389/fmicb.2022.982679
Frontiers in microbiology, Vol. 13 (January 2023) , art. 982679
|
|
|
8.
|
|
8 p, 1.1 MB |
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
/
Encinas, Cristina (Hospital General Universitario Gregorio Marañón (HGUGM). IiSGM) ;
Hernandez-Rivas, José-Ángel (Hospital Universitario Infanta Leonor) ;
Oriol, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
Blanchard, María Jesús (Hospital Universitario Ramón y Cajal (Madrid)) ;
Bellón, José-María (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
García-Sanz, Ramón (Hospital Universitario de Salamanca (IBSAL). CIBERONC e Instituto de Investigación del Cáncer de Salamanca-IBMCC (USAL-CSIC)) ;
de la Rubia, Javier (Hospital Universitari Doctor Peset (València)) ;
López de la Guía, Ana (Hospital Universitario La Paz (Madrid)) ;
Jímenez-Ubieto, Ana (Hospital Universitario 12 de Octubre (Madrid)) ;
Jarque, Isidro (Hospital Universitario la Fe. CIBERONC) ;
Iñigo, Belén (Hospital Clínico San Carlos (Madrid)) ;
Dourdil, Victoria (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
De Arriba, Felipe (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Cuéllar Pérez-Ávila, Clara (Hospital Universitario 12 de Octubre (Madrid)) ;
Gonzalez, Yolanda (Hospital Universitari de Girona Doctor Josep Trueta) ;
Hernández, Miguel-Teodoro (Hospital Universitario de Canarias (La Laguna)) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Granell, Miquel (Institut d'Investigació Biomèdica Sant Pau) ;
Rodríguez-Otero, Paula (Clínica Universitaria de Navarra. CIMA. IDISNA. CIBERONC) ;
Silvent, Maialen (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Cabrera, Carmen (Complejo Hospitalario de Cáceres) ;
Rios, Rafael (Hospital Universitario Virgen de las Nieves (Granada)) ;
Alegre, Adrián (Hospital Universitario de la Princesa. Hospital Universitario Quirónsalud) ;
Gironella, Mercedes (Hospital Universitari Vall d'Hebron) ;
Gonzalez, Marta-Sonia (Hospital Universitario de Santiago) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Ocio, Enrique M. (Hospital Universitario Marqués de Valdecilla. (IDIVAL). Universidad de Cantabria) ;
Krsnik, Isabel (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
García, Antonio (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
García-Mateo, Aránzazu (Hospital General de Segovia) ;
Soler, Joan-Alfons (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Martín Sánchez, Jesús (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Arguiñano, José M (Complejo Hospitalario de Navarra) ;
Mateos, M. V. (Instituto de Investigación Biomédica de Salamanca) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona. CIBERONC) ;
San-Miguel, J (Clínica Universitaria de Navarra. CIMA. IDISNA; CIBERONC) ;
Lahuerta, J. J (Hospital Universitario 12 de Octubre (Madrid)) ;
Martínez-López, Joaquín (Hospital Universitario 12 de Octubre (Madrid))
Infections remain a common complication in patients with multiple myeloma (MM) and are associated with morbidity and mortality. A risk score to predict the probability of early severe infection could help to identify the patients that would benefit from preventive measures. [...]
2022 - 10.1038/s41408-022-00652-2
Blood Cancer Journal, Vol. 12 Núm. 4 (april 2022) , p. 68
|
|
|
9.
|
|
|
10.
|
|
15 p, 2.2 MB |
Influence of sex, age and diabetes on brain transcriptome and proteome modifications following cerebral ischemia
/
Ramiro, Laura (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Faura, Júlia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Simats Oriol, Alba (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Rodríguez, Paula (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ma, Feifei (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martín, Luna (Vall d'Hebron Institut d'Oncologia) ;
Canals, Francesc (Vall d'Hebron Institut d'Oncologia) ;
Rosell Novel, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Montaner, Joan (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Universitat Autònoma de Barcelona
The online version contains supplementary material available at 10. 1186/s12868-023-00775-7.
2023 - 10.1186/s12868-023-00775-7
BMC neuroscience, Vol. 24 (january 2023)
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
